Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-α resistance

Cancer Science

Volumn 98, Issue 8, 2007, Pages 1259-1264

  Shang, Donghao ^a   Liu, Yuting ^a   Ito, Noriyuki ^a   Kamoto, Toshiyuki ^a   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; JANUS KINASE; JANUS KINASE 1; PROTEIN TYK2; PROTEIN TYROSINE KINASE; RECOMBINANT ALPHA2B INTERFERON; STAT PROTEIN; STAT1 PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC TRANSFECTION; IN VITRO STUDY; KIDNEY CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; INTERFERON-ALPHA; JANUS KINASE 1; KIDNEY NEOPLASMS; PHOSPHORYLATION; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANSFECTION; TYK2 KINASE;

EID: 34347259954     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00526.x     Document Type: Article

References (32)

1. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD. How cells respond to interferons. Ann Rev Biochem 1998; 67: 227-64.
2. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-21.
3. Kile BT, Alexander WS. The suppressors of cytokine signalling (SOCS). Cell Mol Life Sci 2001; 58: 1627-35.
4. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 843-52.
5. Lanigan D. Prognostic factors in renal cell carcinoma. Br J Urol 1995; 75: 565-71.
6. Jemal A, Siegel R, Ward E et al. Cancer statistics 2006. CA Cancer J Clin 2006; 56: 106-30.
7. Swanson DA, Quesada JR. Interferon therapy for metastatic renal cell carcinoma. Semin Surg Oncol 1988; 4: 174-7.
8. Bex A, Kerst M, Mallo H et al. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: A consecutive study. Eur Urol 2006; 49: 76-81.
9. Bousquet C, Zatelli MC, Melmed S. Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. J Clin Invest 2000; 106: 1417-25.
10. Owczarek CM, Hwang SY, Holland KA et al. Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2. J Biol Chem 1997; 272: 23.865-70.
11. Pfeffer LM, Wang C, Constantinescu SN et al. Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions. J Urol 1996; 156: 1867-71.
12. Pfeffer LM, Basu L, Pfeffer SR et al. The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action. J Biol Chem 1997; 272: 11.002-5.
13. Gazziola C, Cordani N, Carta S, De Lorenzo E, Colombatti A, Perris R. The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFNα on pleomorphic sarcoma cells. Int Oncol 2005; 26: 129-40.
14. Vlotides G, Sorensen AS, Kopp F et al. SOCS-1 and SOCS-3 inhibit IFN-α-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochem Biophys Res Commun 2004; 320: 1007-14.
15. Shen X, Hong F, Nguyen VA, Gao B. IL-10 attenuates IFN-α-activated STAT1 in the liver: Involvement of SOCS2 and SOCS3. FEBS Lett 2000; 480: 132-6.
16. Zhu H, Nelson DR, Crawford JM, Liu C. Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-α resistance. J Interferon Cytokine Res 2005; 25: 528-39.
17. Hackett RH, Wang YD, Sweitzer S, Feldman G, Wood WI, Larner AC. Mapping of a cytoplasmic domain of the human growth hormone receptor that regulates rates of inactivation of Jak2 and Stat proteins. J Biol Chem 1997; 272: 11.128-32.
18. Stofega MR, Herrington J, Billestrup N, Carter-Su C. Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B. Mol Endocrinol 2000; 14: 1338-50.
19. Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans. Cell 2000; 100: 391-8.
20. Weihofen A, Martoglio B. Intramembrane-cleaving proteases: Controlled liberation of proteins and bioactive peptides. Trend Cell Biol 2003; 13: 71-8.
21. Saleh AZ, Fang AT, Arch AE, Neupane D, El Fiky A, Krolewski JJ. Regulated proteolysis of the IFNaR2 subunit of the interferon-alpha receptor. Oncogene 2004; 23: 7076-86.
22. Horiguchi A, Oya M, Marumo K, Murai M. STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int 2002; 61: 926-38.
23. Zhang YW, Wang LM, Jove R, Vande Woude GF. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 2002; 21: 217-26.
24. Tejman-Yarden N, Zlotnik M, Lewis E, Etzion O, Chaimovitz C, Douvdevani A. Renal cells express a functional interleukin-15 receptor. Nephrol Dial Transplant 2005; 20: 516-23.
25. Schick N, Oakeley EJ, Hynes NE, Badache A. TEL/ETV6 is a signal transducer and activator of transcription 3 (Stat3)-induced repressor of Stat3 activity. J Biol Chem 2004; 279: 38.787-96.
26. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000; 19: 2548-56.
27. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 2004; 3: 11-20.
28. Verra N, de Jong D, Bex A et al. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol 2005; 48: 527-33.
29. Wersall P, Mellstedt H. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and α-IFN. Med Oncol 1995; 12: 69-77.
30. Imai T, Katagiri A, Saito K, Tomita Y. Interferon-α-induced protection of renal cell cancer cell line from lysis by natural killer cells and increase of susceptibility by treatment with 5-fluorouracil. Cancer Lett 1995; 94: 191-7.
31. Brinckmann A, Axer S, Jakschies D et al. Interferon-α resistance in renal carcinoma cells is associated with defective induction of signal transducer and activator of transcription 1 which can be restored by a supernatant of phorbol 12-myristate 13-acetate stimulated peripheral blood mononuclear cells. Br J Cancer 2002; 86: 449-55.
32. Shimazui T, Ami Y, Yoshikawa K et al. Prediction of in.vitro response to interferon-α in renal cell carcinoma cell lines. Cancer Sci 2007; 98: 529-34.